MARKET

AUPH

AUPH

Aurinia Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.72
-0.37
-2.83%
After Hours: 12.88 +0.16 +1.26% 19:54 03/08 EST
OPEN
13.20
PREV CLOSE
13.09
HIGH
13.27
LOW
12.55
VOLUME
3.41M
TURNOVER
--
52 WEEK HIGH
20.50
52 WEEK LOW
9.83
MARKET CAP
1.60B
P/E (TTM)
-8.6619
1D
5D
1M
3M
1Y
5Y
Nephrotic Syndrome Treatment Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
Mar 08, 2021 (Market Insight Reports) -- The Global Nephrotic Syndrome Treatment Market is poised to register a CAGR of over 4% during the forecast period...
Market Insight Reports · 11h ago
Stocks Switch Gears, Dart Higher to End Week
Mar 05, 2021 (Baystreet.ca via COMTEX) -- Equities in Canada's largest centre took some good cheer from south of the border, and jumped sharply to end the...
Baystreet.ca · 3d ago
Lupus Therapeutics Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
Mar 05, 2021 (Market Insight Reports) -- The Global Lupus Therapeutics Market is poised to value over USD 3.2 billion by 2027 end at a CAGR of over 6.2%...
Market Insight Reports · 3d ago
Dry Eye Medication Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
Mar 02, 2021 (Market Insight Reports) -- The Global Dry Eye Medication Market is poised to value over USD 6.62 billion by 2027 end at a CAGR of over 7.0%...
Market Insight Reports · 6d ago
Aurinia Pharmaceuticals to Present at Three Upcoming March Investor Conferences
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the "Company") today announced that members of the executive management team will participate in multiple upcoming investor conferences including the:
BusinessWire · 6d ago
DJ Aurinia Pharmaceuticals Inc. Price Target Cut to $26.00/Share From $28.00 by RBC Capital
Dow Jones · 02/25 17:27
DJ Aurinia Pharmaceuticals Inc. Is Maintained at Outperform by RBC Capital
Dow Jones · 02/25 17:27
American Kidney Fund Announces 2021 Class of Corporate Members Aligned in Fighting Kidney Disease
February 25, 2021 (ACCESSWIRE via COMTEX) -- ROCKVILLE, MD / ACCESSWIRE / February 25, 2021 / The American Kidney Fund (AKF) today announced the 2021 class...
ACCESSWIRE · 02/25 14:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AUPH. Analyze the recent business situations of Aurinia Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AUPH stock price target is 28.19 with a high estimate of 35.00 and a low estimate of 17.90.
EPS
Institutional Holdings
Institutions: 207
Institutional Holdings: 62.46M
% Owned: 49.56%
Shares Outstanding: 126.04M
TypeInstitutionsShares
Increased
50
4.74M
New
43
-1.91M
Decreased
41
9.56M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.02%
Pharmaceuticals & Medical Research
-0.50%
Key Executives
Chairman/Independent Director
George Milne
President/Chief Executive Officer/Director
Peter Greenleaf
Chief Financial Officer
Dennis Bourgeault
Chief Operating Officer
Michael Martin
Executive Vice President/Chief Compliance Officer/General Counsel/Secretary
Stephen Robertson
Executive Vice President
Maxwell Donley
Executive Vice President
Robert Huizinga
Senior Vice President/IR Contact Officer
Glenn Schulman
Chief Marketing Officer
Neil Solomons
Vice President/Director of Sales
Fran Lynch
Vice President/Director of Marketing
Chris Hays
Vice President
Cara Felish
Vice President
Tim Hermes
Other
Max Colao
Director
Daniel Billen
Director
R. Hector MacKay-Dunn
Independent Director
Joseph Hagan
Independent Director
Michael Hayden
Independent Director
David Jayne
Independent Director
Jill Leversage
Independent Director
Timothy Walbert
No Data
About AUPH
Aurinia Pharmaceuticals Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases. It is developing voclosporin in multiple indications. Voclosporin is an investigational therapy. It is developing voclosporin for the treatment of lupus nephritis (LN) and other proteinuric diseases. It is also advancing voclosporin ophthalmic solution (VOS), a topical formulation, for the treatment of dry eye syndrome (DES). Voclosporin is a calcineurin inhibitor (CNI). By inhibiting calcineurin, voclosporin blocks IL-2 expression and T-cell mediated immune responses and stabilizes the podocyte in the kidney.

Webull offers kinds of Aurinia Pharmaceuticals Inc stock information, including NASDAQ:AUPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AUPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AUPH stock methods without spending real money on the virtual paper trading platform.